ADAPTIVE BIOTECHNOLOGIES CORPORATION - COMMON STOC

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

29 Aug 2024 04:30:15 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

22 Aug 2024 13:03:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

01 Aug 2024 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

11 Jul 2024 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

31 May 2024 04:30:26 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

29 May 2024 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports First Quarter 2024 Financial Results

07 May 2024 13:05:46 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024

17 Apr 2024 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

02 Apr 2024 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024

27 Mar 2024 05:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference

22 Feb 2024 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

14 Feb 2024 13:05:54 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024

29 Jan 2024 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

27 Dec 2023 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

09 Dec 2023 05:30:37 By Nasdaq GlobeNewswire

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

05 Dec 2023 04:30:38 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update

09 Nov 2023 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline

07 Nov 2023 04:30:36 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023

02 Nov 2023 13:05:00 By Nasdaq GlobeNewswire

Adaptive Announces Launch of Epic Integration for clonoSEQ®

13 Sep 2023 04:30:49 By Nasdaq GlobeNewswire